On May, 11 The EPS for Leap Therapeutics, Inc. (LPTX) Expected At $-0.51

April 17, 2018 - By Sheila Anderson

On May, 11. Investors expect Leap Therapeutics, Inc. (NASDAQ:LPTX) to report its quarterly earnings, according to Zacks. Analysts expect change of 63.31 % or $0.88 from previous year’s $-1.39 earnings per share compared to current’s $-0.51 earnings per share. -21.54 % EPS growth is what analysts predict. $-0.65 earnings per share was published for last [previous quarter]. Its shares touched $7.49 on during the last trading session after 23.10% change.Leap Therapeutics, Inc. is downtrending after having declined 0.60% since April 17, 2017. LPTX has 708,751 volume or 761.34% up from normal. LPTX underperformed the S&P 500 by 12.15%.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology.The company has $108.61 million market cap. The Company’s clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors.Currently it has negative earnings. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate Leap??s DKK1 antagonist, DKN-01, in combination with Merck??s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: